ADXN addextherapeutics.com: Business Value to Revenue

Public company logo of Addex Therapeutics Ltd. (ADXN)

Addex Therapeutics (ADXN) is scaling the creation of allosteric modulators through B2B partnerships to capture the neuropharmaceutical segment. This EV/Sales multiple chart demonstrates the ratio of capitalization to debt-free revenue, where 27500.00 forms the current metric value. Addex Therapeutics is developing precision drugs for dystonia and Parkinson's disease. A steady influx of patients in the EU and strict FDA/EMA regulations define the development of this ecosystem.

ADXN Addex Therapeutics Ltd. Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Addex Therapeutics Ltd. (ADXN)

Fundamental valuation:Addex Therapeutics (ADXN)
Core merchandise of Addex Therapeutics Ltd

For a comparative asset analysis, the investor utilizes EV/Sales, which compares the total enterprise value to sales volume, excluding the impact of debt load to identify the actual premium paid for revenue. In the case of Addex Therapeutics (ADXN), the trend of the company's value relative to revenue reflects expectations for future allosteric modulators, as current research revenues do not yet align with the potential of maturing pharma partnerships.

Competitor analysis for Addex Therapeutics

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE